Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis
Version of Record online: 18 JUL 2013
Copyright © 2013 American Cancer Society
Volume 119, Issue 19, pages 3489–3495, 1 October 2013
How to Cite
Johnson, D. R., Leeper, H. E. and Uhm, J. H. (2013), Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis. Cancer, 119: 3489–3495. doi: 10.1002/cncr.28259
- Issue online: 19 SEP 2013
- Version of Record online: 18 JUL 2013
- Manuscript Accepted: 18 JUN 2013
- Manuscript Revised: 16 JUN 2013
- Manuscript Received: 2 MAY 2013
- 4RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol. 2013;31(suppl): abstract 1., , , et al.
- 5Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol. 2013;31(suppl): abstract 2002., , , et al.
- 19Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2011 Sub (1973-2010) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission.
- 20Surveillance Research Program, National Cancer Institute. SEER*Stat software, version 8.0.4. http://seer.cancer.gov/seerstat.
- 22R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.